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Background
Pulmonary homografts have been the most widely used
valved conduits for right ventricular outflow tract (RVOT)
reconstruction in the US since mid 1980s. In 1999 a con-
duit containing a bovine jugular vein (Contegra®,
Medtronic, Inc, Minneapolis, MN) was introduced as a
potential alternative for RVOT reconstruction. In 2003,
the bovine jugular vein conduit was released by the FDA
for humanitarian device exemption (HDE) utilization in
centers that obtain institutional review board approval
and have appropriate informed patient consent. Main
advantages of the Contegra® conduit include availability
in sizes from 12–22 mm, natural continuity between the
valve and the conduit that allows proximal infundibular
shaping without additional materials, lower price com-
pared to about half of the pulmonary homografts in the
US, and reduced potential risk of supravalvular stenosis
due to narrowing at the distal suture line. This data has
been reported based on echocardiographic findings of the
Contegra® conduit postoperatively. We report on the use
of cardiac magnetic resonance (CMR) in patients postop-
eratively and compare the findings with echocardiogra-
phy.
Methods
We retrospectively analyzed the results of CMR performed
pre- and postoperatively in 5 patients with the Contegra®
conduit. CMR was performed using a 1.5 Tesla Siemens
Avanto system (Siemens Medical solutions, Malvern, PA).
Standard images for anatomical and functional evalua-
tion, including volume and flow analysis were reviewed.
Descriptive statistical analysis was performed.
Results
The mean age of patients was 20.2 years with average
weight 116.7 lbs and body surface area of 1.57 sq meters.
There were 4 males and 1 female. Primary pathologies
included tetralogy of Fallot (n = 3), double outlet right
ventricle with pulmonary atresia (n = 1) and complex sin-
gle ventricle with pulmonary atresia (n = 1). The average
time period between the placement of the Contegra® con-
duit and CMR was 12 months. The mean right ventricular
end-diastolic volume to left ventricular end-diastolic vol-
ume ratio RVEDP: LVEDP) preoperatively was 1.6 and
postoperatively was 1.3. The conduit and the neo-pulmo-
nic valve were well visualized on CMR in all 5 patients,
whereas only 3 patients' echocardiograms were able to vis-
ualize the Contegra® conduit well. In addition, CMR was
able to quantify the right ventricular function and degree
of pulmonic regurgitation, if any. The conduit was not
dilated in any of the 5 patients. Although minimal pulmo-
nic regurgitation was noted on CMR in 3 of the 5 patients,
this was significantly better than on the preoperative
CMR. None of the patients experienced any complications
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related to the magnetic field. The quality of the images of
the Contegra® conduit compared well with other pros-
thetic valves on CMR (Figure 1).
Conclusion
The Contegra® conduit is safe to image with CMR, even as
early as a year postoperatively, CMR provides excellent
images and reliable data regarding the functionality of the
conduit with relative ease when compared to echocardi-
ography. This is a promising alternative for following
patients with RVOT reconstruction to assess the Contegra®
conduit and neo-pulmonic valve, degree of pulmonary
regurgitation or stenosis, and right ventricular function.
Images 1 and 2 represent images from a patient with Contegra® conduit and images 3 and 4 are from a patient with a St. Jude Biocor® porcine pulmo ic valvF gure 1
Images 1 and 2 represent images from a patient with Contegra® conduit and images 3 and 4 are from a patient with a St. Jude 
Biocor® porcine pulmonic valve.Page 2 of 2
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